Veliparib

Active substance
Veliparib
Domain
Oncology and Hematology
Reason of inclusion in Horizonscan Geneesmiddelen
New medicine (specialité)
Main indication
Breast cancer
Extended indication
Breast cancer; HER2-negative metastatic or locally advanced unresectable BRCA-associated - first to third-line in combination with carboplatin and paclitaxel.

1. Product

Manufacturer
Abbvie
Mechanism of action
PARP inhibitor
Route of administration
Oral
Therapeutical formulation
Capsule
Budgetting framework
Intermural (MSZ)
Additional comments
PARP-remmer

2. Registration

Registration route
Centralised (EMA)
Submission date
July 2020
Expected Registration
August 2021
Orphan drug
No
Registration phase
Clinical trials

3. Therapeutic value

Current treatment options
Concurrentie van alle parp-remmers.
Therapeutic value
No judgement
Duration of treatment
Not found

4. Expected patient volume per year

Patient volume

< 189

Market share is generally not included unless otherwise stated.

References
NKR
Additional comments
NKR 2015: 1.885 mammacarcinomen HER- stadia 3 en 4. 5-10% van borstkankers wordt veroorzaakt door BRCA mutaties.

5. Expected cost per patient per year

Cost
30,000 - 60,000
Additional comments
Afhankelijk van de behandelduur vergelijkbaar met olaparib en rucaparib. Inschatting €30.000-€60.000.

6. Potential total cost per year

Total cost

8,505,000

This amount gives an indication of the total cost. It is the result of the average expected patient volume times the average cost per patient. both per year.

7. Off label use

There is currently nothing known about off label use.

8. Indication extension

Indication extension
No
References
adisinsight
Additional comments
Buiten de indicaties in de Horizonscan geen nieuwe indicatie-uitbreidingen.

9. Other information

There is currently no futher information available.